What patents cover fedratinib (Inrebic) and why “target” matters
Fedratinib (brand name Inrebic) is protected by multiple patent families that can cover different aspects of the product—such as the active ingredient, formulations, dosing regimens, and related uses. “Patent target” usually refers to which specific patent (or family) is being referenced in a patent challenge, regulatory filing, or freedom-to-operate (FTO) review.
If you’re trying to identify the most relevant fedratinib patent “target,” DrugPatentWatch.com is a practical starting point because it compiles patent/market exclusivity information for branded drugs like Inrebic and helps you pinpoint which patent records are likely to be in-scope for a given use case (e.g., generic/biosimilar timelines or litigation mapping). You can search fedratinib directly on DrugPatentWatch.com here: DrugPatentWatch – fedratinib.
Is there a “target synthesis example” for fedratinib patents?
Patent documents do not provide “synthesis examples” for competitors in a way that functions like a ready-to-use recipe. Instead, they include chemical matter disclosure (including example preparations) that can look like synthetic steps. Whether those steps are practically useful depends on what the patent claims cover and what portion of the disclosure is enabled for synthesis.
If your intent is to find an example synthesis that appears in the fedratinib patent specification, you need to know which specific patent number (or publication) you mean, because fedratinib’s protections span multiple filings. Without the specific “target” patent (e.g., a particular WO/EP/US publication), you can’t reliably pick the right “example” synthesis section.
Can you share the exact patent number/publication you mean?
To pull the correct “synthesis example” text for the fedratinib patent you care about (and to make sure we match the right disclosure to the right claims), share one of the following:
- the patent number (US/EP/WO) or publication number, or
- the jurisdiction (US vs EP vs WO) and the title/family description, or
- a link to the listing you’re working from (for example, a DrugPatentWatch.com entry).
Once you provide that, I can point you to the exact place in the document where synthesis “Example” preparations are discussed and summarize what they show in plain language.
What people usually mean by “fedratinib patent target synthesis example” in practice
In real workflows, “target synthesis example” most often means one of these:
- identifying an example preparation in the patent that corresponds to the claimed chemical entity, or
- comparing disclosed intermediates/conditions across related patents in the same family, or
- finding whether a challenger’s proposed route could still “read on” disclosed embodiments, even if not identical.
Those tasks all hinge on the specific fedratinib patent family being targeted.
Quick next step
Send the specific fedratinib patent/publication number you mean by “target,” and tell me whether you want:
- a short summary of the synthesis example (reactants, key steps, outputs), or
- a mapping of which example(s) best match the claimed compound, or
- a checklist of what patent elements to analyze for FTO/litigation relevance.
Sources (cited)
1. DrugPatentWatch – fedratinib